Untreated melanoma follows a broadly predictable path: it grows deeper into the skin, invades lymphatic channels, spreads to regional lymph nodes, and eventually seeds distant organs including the brain, lungs, and liver. The timeline varies enormously depending on the melanoma’s subtype and thickness, but the endpoint without treatment is almost always fatal. About 80 percent of people with distant-stage melanoma die from the disease itself, and the ways it kills are often organ failure, progressive wasting, or neurological collapse.
What Happens at the Primary Site
A melanoma that is never excised does not simply sit there. It continues growing outward across the skin surface and, more dangerously, downward through the layers of the dermis. As it thickens, it becomes more likely to ulcerate, meaning the skin covering the tumor breaks down. Ulceration is one of the strongest independent predictors of whether cancer has already spread to the sentinel lymph node, along with thickness and how rapidly the cells are dividing.
Once a melanoma breaks through the skin surface, the resulting wound behaves unlike a normal cut or scrape. Malignant wounds grow quickly and tend to produce a cycle of necrosis, bacterial colonization, and heavy drainage. The dead tissue liquefies as bacteria activate enzymes that break it down, generating foul-smelling exudate. Bleeding is common because the tumor disrupts the normal clotting process. Pain, swelling, and secondary infection are typical companions.1SpringerOpen / Springer PMC. Management of malignant cutaneous wounds in oncologic patients For someone who never seeks treatment, this means an open, worsening wound that does not heal, bleeds unpredictably, and becomes increasingly painful over months.
Invasion Into the Lymphatic System
Melanoma cells gain access to the rest of the body primarily through the lymphatic system, the network of vessels and nodes that normally drains fluid from tissues. When researchers used specialized staining techniques to look for lymphatic invasion in melanoma samples, they found it in roughly a quarter of cases. The melanomas that had invaded lymphatic channels were thicker, had higher rates of cell division, and were more frequently ulcerated. Among tumors with confirmed lymphatic invasion, a third had already spread to the sentinel lymph node, compared with about one in ten tumors without that invasion.2PubMed. Lymphatic invasion predicts sentinel lymph node metastasis and adverse outcome in primary cutaneous melanoma
Before melanoma reaches regional lymph nodes, it can form what are called satellite and in-transit metastases. These are small tumor deposits that lodge in the skin or just beneath it, between the primary tumor and the nearest lymph node basin. They appear as firm nodules, typically darker than surrounding skin, and on ultrasound they look like solid, well-defined lumps that are darker than the surrounding fat.3PubMed. Sonographic evaluation of clinically occult in-transit and satellite metastases from cutaneous malignant melanoma In one large review, about 2 percent of melanoma patients developed these in-transit deposits, and those who had them at the time of initial diagnosis had markedly worse survival.4PubMed. Satellite and In-Transit Metastatic Disease in Melanoma Skin Cancer: A Retrospective Review of Disease Presentation, Treatment, and Outcomes Two percent may sound small, but it reflects the fraction caught during routine care. Without treatment, the proportion would be higher, since nothing is removing or controlling the primary tumor.
Where Melanoma Spreads in the Body
Once melanoma cells enter the bloodstream, they can lodge in virtually any organ. The process involves tumor cells physically sticking to the inner lining of blood vessels at distant sites, anchoring themselves, and establishing new colonies. Research on melanoma cell adhesion has shown this attachment is driven by specific molecular interactions between proteins on the tumor cell surface and receptors on blood vessel walls.5PubMed Central. Anti-gicerin Antibody Suppresses Early Pulmonary Metastatic Colonization of B16F10 Melanoma Cells The organs that melanoma favors most are the brain, lungs, liver, bone, and skin itself.
Brain
The brain is one of melanoma’s most common distant targets, and brain metastases are a major contributor to death. Roughly 37 percent of patients with stage IV melanoma develop brain metastases that are detectable during their lifetime. Autopsy studies paint an even grimmer picture, finding brain involvement in 55 to 75 percent of people who died from melanoma.6PubMed Central. Metastatic malignant melanoma of unknown primary site to the brain: A case report Symptoms depend on where the tumors land but commonly include headaches, seizures, personality changes, weakness on one side of the body, and difficulty with speech or vision. Older autopsy data found that about a third of melanoma deaths were attributable to central nervous system involvement.7European Journal of Cancer. The current causes of death in patients with malignant melanoma
Liver
Liver metastases are especially dangerous because they can progress silently until the organ is overwhelmed. In rare but documented cases, melanoma infiltrates the tiny blood channels (sinusoids) within the liver so extensively that the organ fails acutely. The tumor cells obstruct blood flow through the liver, causing liver cells to die from lack of oxygen. This produces a dramatic spike in liver enzymes and rapid-onset liver failure with jaundice, pain, and confusion. The prognosis once this happens is measured in days to months.8PubMed Central. Metastatic melanoma: an unexpected cause of acute liver failure Studies of how liver metastases develop from ocular melanoma have shown that tiny dormant tumor clusters, too small to detect on imaging, can be present in the liver long before symptoms arise. These microscopic deposits gradually acquire their own blood supply and begin actively dividing, eventually growing into larger masses.9PubMed Central. Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture
Lungs and Bone
Lung metastases were historically cited as the second most common cause of melanoma death after brain involvement. Pulmonary spread can cause coughing, shortness of breath, chest pain, and eventually respiratory failure. Bone metastases, while less common, can be devastating. In one reported case, a 39-year-old man with disseminated melanoma presented with what seemed like lingering ankle pain after a sprain, which turned out to be a pathological fracture of his shinbone caused by melanoma that had eaten through the bone.10Foot and Ankle Surgery. Pathologic fracture of the distal tibia secondary to melanoma: A case report of a very rare entity Bone metastases from melanoma can cause fractures from routine activity, severe pain, and spinal cord compression if the spine is involved.
Cachexia and Systemic Decline
Even before organ failure sets in, advanced melanoma triggers a devastating syndrome called cachexia. This is not simply losing weight from poor appetite; it is a metabolic rewiring driven by the cancer itself. The body begins breaking down muscle and fat at accelerated rates that eating alone cannot reverse. Research in melanoma-induced cachexia has shown that it progressively damages multiple organ systems. Skeletal muscle wastes profoundly, and there are measurable increases in an enzyme called ACE across wasting tissues as the disease advances.11Cell Reports. Progressive development of melanoma-induced cachexia differentially impacts organ systems in mice People with advanced melanoma cachexia become profoundly weak, lose the ability to perform everyday activities, and become increasingly vulnerable to infections because their immune system is stretched thin fighting both the cancer and the body’s deterioration.
How People With Advanced Melanoma Die
A recent study of patients with advanced melanoma in the modern treatment era found that the vast majority, about 88 percent, died from melanoma-specific causes. The most common cause of death was progressive failure to thrive, accounting for roughly 58 percent of deaths. Respiratory failure was next at about 22 percent, followed by infection at a similar rate.12PubMed Central. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era “Failure to thrive” in this context means the gradual shutdown of bodily functions as the cancer overwhelms the body’s ability to sustain itself. It is often the cachexia described above combined with multi-organ compromise.
A broader population-level study of melanoma patients in the United States found that the percentage of deaths rises sharply with stage. In localized melanoma, the majority of deaths were actually from non-cancer causes like heart disease and stroke, with only about a quarter dying from melanoma itself. But in distant-stage melanoma, the disease itself was overwhelmingly the killer, with 80 percent of patients dying from their cancer.13PubMed Central. Causes of death among patients with cutaneous melanoma: a US population-based study This underscores the point that the question is not really whether untreated melanoma will become fatal, but how quickly.
How Much Delay Actually Matters
One of the clearest pieces of evidence for what happens when melanoma goes untreated comes indirectly from studies on surgical delay. Even modest delays between diagnosis and surgical removal make a measurable difference. A large study found that waiting more than 29 days from biopsy to definitive surgery was associated with a 34 percent increase in melanoma-specific death and a 25 percent increase in death from any cause. Evaluated continuously, every additional 30-day delay was linked to a 10 percent increase in melanoma death and an 8 percent increase in overall death.14PubMed Central. Surgical delay and mortality for primary cutaneous melanoma If a one-month delay raises mortality by 10 percent, imagine what happens when the delay is permanent. The tumor keeps thickening, keeps invading deeper, and keeps gaining access to the lymphatic and vascular systems.
Melanoma Types That Often Get Missed
Part of why melanoma sometimes goes untreated is that certain subtypes are easy to miss entirely. Amelanotic melanoma, a variant that lacks the dark pigmentation people associate with skin cancer, is among the most commonly misdiagnosed. Because it can appear pink, red, or skin-colored, it mimics a range of benign conditions including warts, fungal infections, and inflammatory skin diseases. Misdiagnosis rates for amelanotic melanoma have been reported as high as 89 percent.15PubMed Central. Amelanotic nodular melanoma misdiagnosed as a benign skin lesion: A rare case report from Syria These lesions lack the classic warning signs taught in public awareness campaigns, so neither patients nor clinicians always recognize what they are looking at.16American Journal of Case Reports. Diagnostic Delays in Metastatic Amelanotic Melanoma Presenting as Breast Pain
Acral lentiginous melanoma, which appears on the palms, soles, and under fingernails or toenails, presents a different diagnostic trap. These areas are not typically associated with sun damage, so both patients and doctors may not think “melanoma” when they see a dark streak under a nail or a discolored patch on the sole of a foot. One documented case involved a man who had a pigmented lesion on his great toe for 12 years. When it was first biopsied five years in, it showed only early abnormal changes without invasion. By the time it was biopsied again, it had progressed to invasive stage IIIB melanoma with lymph node involvement.17PubMed Central. Progression from Acral Lentiginous Melanoma in situ to Invasive Acral Lentiginous Melanoma That case shows the slow-burn nature of some melanomas: they can simmer for years before becoming aggressive, giving a false sense of safety.
Spontaneous Regression and Melanoma of Unknown Primary
One of the strangest aspects of melanoma biology is that a small fraction of primary tumors partially or completely regress on their own. The immune system occasionally mounts an effective attack against a melanoma, destroying it in whole or in part. Research into how this happens has found that the earliest immune responders appear to be a specialized population of macrophages and natural killer cells, with the T cells and B cells that most people think of as cancer fighters arriving only later in the process.18PubMed Central. Deciphering the immune reaction leading to spontaneous melanoma regression: initial role of MHCII(+) CD163(-) macrophages
This phenomenon creates a paradox that catches clinicians off guard. Sometimes a patient shows up with metastatic melanoma in the lymph nodes, brain, or another organ, but no primary skin lesion can be found. This is called melanoma of unknown primary, and the leading explanation is that the body’s immune system destroyed the original skin tumor after it had already sent metastatic cells elsewhere.19Journal of Surgical Oncology. Melanoma of unknown primary In these patients, the skin may show telltale signs like patches of vitiligo-like depigmentation or grey macules where pigment has been cleared, suggesting that immune cells attacked both the melanoma and nearby normal pigment-producing cells.20PubMed. Metastatic melanoma of unknown primary: an unusual dermatologic presentation
Spontaneous regression should not be mistaken for a reason to delay treatment. The immune response is rarely complete enough to eliminate every tumor cell. A melanoma that appears to have regressed may still have scattered viable cells in the skin or micrometastases that have already seeded distant organs. In fact, melanomas showing partial regression can pose a staging dilemma because the original tumor’s true thickness, the single most important factor in predicting spread, may have been greater than what remains to measure.21PubMed. Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients A thinner-looking tumor at biopsy could mask a history of deeper invasion and higher metastatic risk.
Dormant Metastases and Late Recurrence
Even when a melanoma appears to have been caught early or seems to be behaving indolently, the disease has a well-documented capacity for late recurrence. Melanoma cells can lie dormant in distant organs for years or even decades. The liver metastasis research mentioned earlier showed that the smallest tumor deposits found at autopsy were avascular and not actively dividing, essentially sleeping.9PubMed Central. Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture Something eventually triggers these dormant clusters to switch on, develop a blood supply, and begin growing. What flips that switch is not fully understood, but the clinical consequence is clear: people who were declared cancer-free after melanoma treatment can develop metastatic disease five, ten, or fifteen years later. For someone who never received treatment at all, these dormant deposits would simply grow unchecked whenever they activate.
This dormancy also helps explain why melanoma’s reputation as unpredictable is well earned. Two tumors that look identical under the microscope can behave very differently. One may metastasize within months; another may stay confined to the skin for years before becoming aggressive. Thickness, ulceration, and rate of cell division are the strongest predictors of which tumors will spread, but they are probabilities, not certainties.21PubMed. Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients The unpredictability is part of what makes the decision to leave melanoma untreated so dangerous: even a seemingly stable lesion can shift without warning.